EMA synthetic peptide guideline, and what changes for European research supply.

The European Medicines Agency Committee for Medicinal Products for Human Use issued the final adopted text of the Guideline on the Development and Manufacture of Synthetic Peptides in late 2025. The reference number is EMA/CHMP/SWP/513712/2024. The guideline takes legal effect for new regulatory authorisation applications from June 2026 forward.

For pharmaceutical manufacturers, the guideline tightens expectations around impurity characterisation, control of related substances, and process validation. For European research compound supply, the guideline does not regulate the same activities. It does, however, raise the floor on what the broader peptide supply chain considers acceptable analytical practice, which has indirect consequences for everyone who tests, sells, or buys peptides in Europe.

This piece walks through what the guideline actually requires, who it applies to, and what changes for a research-use European supplier like Cresten Labs.

Who the guideline regulates

The guideline applies to applicants seeking regulatory authorisation for medicinal products containing synthetic peptide active substances. It does not apply to peptides supplied for research use only, in vitro testing, preclinical investigation, or laboratory reagent applications. The legal basis for the distinction is Article 1(2) of Directive 2001/83/EC, which defines a medicinal product by intended use and presentation, not by the chemical identity of the active substance.

A peptide synthesised, packaged, and labelled for research use, with no claims of therapeutic efficacy, no dosing guidance for human use, and proper research-use-only documentation accompanying the supply, is not a medicinal product under European law. It does not require regulatory authorisation, and the EMA guideline does not regulate its manufacture or supply.

This distinction matters operationally. A research-grade peptide supplier is governed by general European product safety law (Regulation (EU) 2023/988), commercial chemicals legislation under REACH where applicable, and country-specific medicines law where the supply could be construed as a medicinal product. The supplier is not governed by EMA pharmaceutical manufacturing standards, ICH Q7 GMP, or the new synthetic peptides guideline.

What the guideline expects from manufacturers

The guideline expects pharmaceutical applicants to characterise peptide impurities according to the framework already established for small-molecule active substances under ICH Q3A and ICH Q3B, with synthetic-peptide-specific adaptations. The major adaptations are:

• Identification thresholds for related substances are set at 0.10 percent for peptides up to about 80 residues, with case-by-case justification above that.
• Qualification of impurities follows a tiered approach. Below the identification threshold, no qualification is required. Above the qualification threshold (typically 0.15 percent), structural identification and toxicological qualification are expected.
• Residual solvents, residual reagents, and process-derived impurities (truncation products, incomplete deprotection products, deamidation products) are explicitly enumerated and require validated analytical methods for control.
• Stability indication during storage requires characterisation of the major degradation pathways, typically including oxidation of methionine and tryptophan residues, deamidation of asparagine and glutamine residues, and aggregation behaviour.

For a pharmaceutical manufacturer, this is a meaningful tightening of what was previously a more flexible interpretive framework. Impurities that were previously controlled by general specification language now have specific named methods and named thresholds. Audit trails for analytical method validation are expected to be at the level of pharmaceutical product release rather than at the level of process intermediates.

What changes for research supply

The direct legal answer is that nothing changes for research supply, because research supply was not in scope. The indirect answer is that several things shift in the surrounding analytical ecosystem.

Janoshik and the testing labs

Third-party analytical labs that serve both pharmaceutical applicants and research-use customers will update their default methods to reflect the new guideline. This is already happening at Janoshik Analytical, which serves Cresten Labs. The standard HPLC method for peptide purity assessment now reports related substances at the 0.10 percent threshold rather than the 0.50 percent threshold that was common in 2023. The standard MS confirmation includes higher resolution requirements. The standard endotoxin LAL test is run at lower detection limits.

For a research-use buyer, this means the COA accompanying a Cresten batch in 2026 contains more information than the equivalent COA from 2023 would have contained. Same lab, same compound, more characterisation. The shift is voluntary on the lab side, driven by the lab's pharmaceutical-customer base, but the benefit accrues to research customers as well.

Synthetic process controls

Peptide synthesis suppliers (the upstream labs that synthesise the bulk peptide before it is purified, lyophilised, and supplied) are similarly being pulled toward higher process-control standards. A supplier serving a pharmaceutical client who is following the new guideline will run the same process, with the same controls, for research-use clients. The process does not have two settings.

This means the structural baseline for research peptide quality is higher in 2026 than it was in 2023. A 99.5 percent purity peptide with characterised impurity profile and validated analytical methodology is now achievable at a price point that would have been unrealistic three years ago.

Documentation expectations

Research customers are reading certificates more carefully. Accredited researchers and laboratory buyers increasingly request complete analytical packages: the HPLC chromatogram with related substances explicitly labelled, the LC-MS identity confirmation, the endotoxin LAL result, the residual solvents panel, the synthesis date, and the testing lab's reference number. Accredited re-verification by a third-party laboratory is increasingly common practice. This is downstream of the regulatory tightening. Buyers now expect what the new guideline requires for medicinal products, even when buying for research use.

A supplier who responds to that expectation by publishing complete, batch-specific, third-party verified documentation has a structural advantage. A supplier who does not is increasingly a target for buyer scrutiny.

What does not change

The research-use jurisdictional framework is unchanged. Peptides supplied for laboratory research, with research-use-only labelling, no therapeutic claims, no human-use dosing guidance, and proper acknowledgment from the buyer at point of order, remain legal under European law. Cresten Labs operates under this framework and has no plans to change.

The EMA guideline does not create a new category of regulated activity for research compound supply. It does not require Cresten or its peers to register as pharmaceutical manufacturers. It does not subject batch testing to GMP audit. It does not bring research-use peptides into the scope of medicinal-product law.

What it does do is raise the floor on what European researchers should expect from any supplier of peptide compounds. The floor is now: tested, batch-traceable, characterised to 0.10 percent, identity-confirmed by orthogonal mass spectrometry, with the full report available before purchase.

That floor is what we built Cresten to meet.